Every registered pharmaceutical premises in Nigeria must be directly supervised by a superintendent pharmacist, and the registration lapses if the premises trades for thirty continuous days without one. That is not a technicality in a market where pharmacists emigrate. Your distributor’s right to hold and move your product can end because an individual resigned and was not replaced inside a month.
Start with who pays, because it decides who you sell to. Around three quarters of health spending in Nigeria comes straight out of patients’ pockets, and that proportion has barely moved in a decade. Federal health allocation has sat near four to five per cent of the budget against the fifteen per cent the Abuja Declaration contemplated. Insurance is growing — national scheme enrolment has passed twenty-three million, with cost-sharing arrangements appearing in oncology — but it is not yet the market. The market is private, retail and paid for in cash.
Something has changed on the public side, though, and it is worth tracking. A national group purchasing organisation now exists, approved at federal executive level and brought into being under a concession agreement signed in February 2026, explicitly to use government’s buying power — starting through the basic healthcare fund and extending later to federal tertiary hospitals. That is the most consequential change to Nigerian public pharmaceutical procurement in years, and it changes who a distributor needs to be registered with.
Supply is mostly imported, and the local base is concentrated at the simple end. Industry figures put roughly seventy per cent of medicines consumed as imported, with well over a hundred local manufacturers of whom most also import. The pattern is visible line by line: one common antibiotic has over ninety registered importers against twenty-one domestic producers. A tariff structure that gives zero duty on finished essential medicines while taxing raw materials has not helped the formulators.
Then there is the channel, and this is where Nigeria is genuinely unlike its neighbours. The country legislated a complete distribution ladder in 2012, with manufacturers and importers permitted to supply only designated state and mega centres, those centres supplying wholesalers, and wholesalers supplying pharmacies and approved vendors. Compliance was due by the end of 2013. It has not happened nationally, and a January 2026 policy assessment concluded implementation had stalled.
The same Act goes further than most brand owners expect, and it is a corporate rule rather than an agency one. A company that manufactures, imports, exports, stores, distributes or wholesales medicines must have at least one registered pharmacist on its board who is also a shareholder; a chain retail company needs a Nigerian pharmacist on the board holding at least forty per cent. So a foreign brand owner cannot simply incorporate a wholly owned importing entity and staff it. There is a seat on the board that has to be filled by a particular kind of person, with equity.
The channel itself is the other thing to understand, because the paper and the reality diverge. Nigeria legislated a complete distribution ladder in 2012 — manufacturers and importers supplying only designated centres, those centres supplying wholesalers, wholesalers supplying pharmacies — with a compliance deadline of December 2013. It passed. So did deadlines in 2017 and 2018. As of now the coordinated wholesale model is operationally in force in Kano, by virtue of a specific Federal High Court order, and the open markets remain the de facto wholesale layer in the south.
The centre of gravity in the south remains the open drug markets: Idumota in Lagos, Ogbo-Ogwu at Onitsha — described by that state’s governor as the largest open drug market in Africa — and Ariaria in Aba. They persist because they are embedded economic systems providing livelihoods and generating rents, not merely because enforcement has been lax. Any shortlist that pretends they do not exist is describing a different country.
Kano is the exception, and the mechanism matters. A Federal High Court judgment in February 2024 ordered relocation to a coordinated wholesale centre, and enforcement followed within days: around one thousand three hundred and seventy wholesale outlets and packing stores sealed, with owners told to report to the regulators at the new centre. Elsewhere, relocation has been tied to centres being built, and as of mid-2025 the southern markets had none, so enforcement there ran through compliance fines instead.
Above the markets sits a thin formal tier with real physical requirements. A wholesaler needs premises of at least seventy square metres; a mega distributor needs three separate storage areas of at least a hundred square metres each, plus a superintendent with ten years post-qualification and a pharmacist on the board with the same. A candidate claiming mega distributor standing without three hundred-square-metre stores is claiming a tier it does not hold, and the premises measurement sits in the inspection report.
Below everything, and impossible to ignore, are the patent and proprietary medicine vendors: more than two hundred thousand of them, licensed by the Council, restricted to an approved list, and expressly excluded from the distribution practice guidelines. They are the first point of care for most under-five fever cases. Pharmacy chains exist and are real, but they are Lagos-weighted and sub-scale; none approaches national coverage, and the largest counts published are now two to three years old.
Nigeria’s requirements are unusually document-rich, which is helpful: almost everything can be evidenced, and the absence of a dated artefact is itself the finding.
The first three can stop supply overnight regardless of commercial performance, so they come before any conversation about targets or territory.
Check the category covers the activity they propose to carry out for you, and that the retention fee for the current year is paid. An unpaid fee past the end of March is not an administrative detail: the Council may close the premises and strike it off.
A company manufacturing, importing, exporting, storing, distributing or wholesaling medicines must have a registered pharmacist on its board who holds shares. Ask for the certified particulars of directors and the register, and match the named pharmacist to their own registration.
Registration lapses if the premises operates thirty continuous days without a superintendent. Get their current licence, their undertaking that this is their only full-time role, and ask what the succession plan is. Pharmacist emigration makes this a live risk rather than a theoretical one.
The temperature mapping report, the calibration and alarm-test records, and the last annual recall challenge with its reconciliation. A compliant operation already holds all three. Ask for the files by name and read the dates rather than accepting a summary.
The guidelines require sourcing only from authorised suppliers and recording the authorisation check on receipt. Pick ten recent consignments and ask to see the recorded verification. Then confirm they can produce ten years of distribution records on request, because that is the retention standard.
Seventy square metres for a wholesaler; three storage areas of a hundred square metres each for a mega distributor, with a ten-year superintendent and a ten-year pharmacist on the board. The measurement is in the inspection report, so this is a reading exercise, not an argument.
In Kano an open-market address is now unlawful by court order. In Lagos, Onitsha and Aba the markets are still where the trade is, but they are the stated target of the next enforcement wave. Knowing which you are buying matters to your continuity planning.
Ask how they handle unique identifiers for the phased categories under the 2024 traceability regulations, and if they sell online or supply anyone who does, ask for the electronic pharmacy licence and their connection to the national platform.
Thirty continuous days trading without a superintendent and the premises registration is gone. The commercial symptom is a distributor that suddenly cannot receive or release stock, and the cause is a resignation nobody told you about. This is the most under-asked question in Nigerian pharmaceutical distribution.
Coordinated raids on the three southern markets in early 2025 seized and destroyed well over a hundred forty-foot truckloads of counterfeit and substandard product, and a Lagos trade fair raid the following year seized around ten million doses of counterfeit malaria medicine. Enforcement is episodic and heavy rather than continuous and light.
The most persistent Nigerian failure is distribution and storage, not manufacture. Policy analysis cites a regulator study in which a large majority of oxytocin samples failed stability testing, attributed to improper storage and handling. Your product can be genuine, in-date, and no longer work.
The standard penalty for breaching storage and distribution practice has been reported at two million naira, often settled at a quarter of that. A distributor can treat non-compliance as a cost of doing business. You cannot, because the product that fails is yours.
A legislated channel architecture with a missed 2013 deadline is still being enforced market by market through court orders and seals. Planning on either outcome — that it will never happen, or that it has already happened — has caught people out. Build for both.
Local manufacturers reportedly import the overwhelming majority of their active ingredients, and a presidential duty concession on pharmaceutical raw materials and machinery is expected to lapse in 2027 with the industry asking for an extension. A local supply chain is not automatically an insulated one.
Yes, and as a shareholder. Under the Pharmacy Council of Nigeria Act 2022 a company engaged in manufacturing, importation, exportation, storage, distribution or wholesale of medicines must have at least one registered pharmacist on its board who also holds shares. A chain retail pharmacy company needs a Nigerian pharmacist on the board owning at least forty per cent. This is a corporate ownership rule, not an agency rule, and it means a wholly owned foreign importing entity is not straightforward.
Premises registration lapses if the premises operates for thirty continuous days without one, and any change of superintendent requires the registrar’s approval. Given that pharmacists are emigrating, this is a real continuity risk, so ask for the superintendent’s current licence, their undertaking that this is their only full-time job, and what the cover arrangement is.
Not nationally. Kano’s wholesale cluster was sealed in February 2024 under a Federal High Court order directing relocation to a coordinated wholesale centre, with around one thousand three hundred and seventy outlets affected. Lagos, Onitsha and Aba were directed to relocate once centres are built, and as of mid-2025 those states had none. A January 2026 assessment found implementation had stalled, and the regulator was still speaking of closure without a deadline in September 2026.
Yes, and it is a current numbered instrument effective from November 2024. It requires a designated responsible person who is the superintendent pharmacist, sourcing only from authorised suppliers with the authorisation check recorded on receipt, segregated storage for rejected, expired, recalled and suspect product, temperature mapping, annual calibration, six-monthly alarm testing, an annual challenge of the recall procedure, and record retention of at least ten years.
Increasingly through one counterparty. A national group purchasing organisation was approved in 2025 and brought into effect by a concession agreement in February 2026, beginning with the basic healthcare fund and extending to federal tertiary hospitals. Public health allocation remains modest at around four to five per cent of the federal budget, so the volume is still private and out-of-pocket.
The position is materially easier than in 2022 and 2023. The central bank issued a new foreign exchange manual in May 2026, effective that June, its first comprehensive revision in eight years, covering capital importation, certificate issuance and repatriation. Reserves and the parallel market premium both improved through 2026. The binding constraint now is the cost of money rather than access to it.
The things that stop supply in this market are documents and people rather than demand, and they are checkable before you commit. Tell us what you are placing and we will come back on the structure, the exposures we would want closed, and the candidates.
How we verify How a distributor search runs